Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H29N3O4 |
Molecular Weight | 435.5155 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](CNCCC1=CC=C(NC[C@H](O)C2=CC=CC=C2)C=C1)C3=CC=C(O)C(NC=O)=C3
InChI
InChIKey=BMKINZUHKYLSKI-DQEYMECFSA-N
InChI=1S/C25H29N3O4/c29-17-28-22-14-20(8-11-23(22)30)24(31)15-26-13-12-18-6-9-21(10-7-18)27-16-25(32)19-4-2-1-3-5-19/h1-11,14,17,24-27,30-32H,12-13,15-16H2,(H,28,29)/t24-,25-/m0/s1
Molecular Formula | C25H29N3O4 |
Molecular Weight | 435.5155 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Milveterol (also known as GSK159797) was developed as a longer-acting beta2 adrenoceptor agonist for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Milveterol completed phase II clinical trials for asthmatic subjects. However further development of the drug was discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00358488
GSK159797 (10, 15, and 20mcg) following dosing for 14 days
Route of Administration:
Respiratory
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:55:00 GMT 2023
by
admin
on
Sat Dec 16 16:55:00 GMT 2023
|
Record UNII |
LGY1VQ9622
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LGY1VQ9622
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
9892481
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
DB05043
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
8870
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
300000034306
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
C77935
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL1940832
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
652990-07-3
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY | |||
|
DTXSID30215640
Created by
admin on Sat Dec 16 16:55:00 GMT 2023 , Edited by admin on Sat Dec 16 16:55:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|